Company news

Vertex Pharmaceuticals Incorporated news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Vertex Reports Third Quarter 2026 Financial Results

November 2, 2026

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 2026

October 23, 2026

Vertex Appoints Daniel Brennan to its Board of Directors

October 20, 2026

Vertex to Present New Data on ALYFTREK® at the North American Cystic Fibrosis Conference

October 9, 2026

Vertex to Announce Third Quarter 2026 Financial Results November 2nd

October 7, 2026

Vertex Announces Positive Results From Phase 2b AMPLIFIED Study of Inaxaplin in Additional Populations of People With APOL1-Mediated Kidney Disease (AMKD) and Completion of Enrollment in the Phase 2/3 AMPLITUDE Trial

September 22, 2026

Vertex Partners With World Champion Skier Lindsey Vonn to Raise Awareness of JOURNAVX®, a Non-Opioid Medicine Approved for the Treatment of Moderate-to-Severe Acute Pain

September 15, 2026

Vertex Partners With World Champion Skier Lindsey Vonn to Raise Awareness of JOURNAVX®, a Non-Opioid Medicine Approved for the Treatment of Moderate-to-Severe Acute Pain

September 15, 2026

Vertex Completes Acquisition of Crinetics Pharmaceuticals and Announces Expansion of Executive Leadership Team

September 1, 2026

Quarterly Report for Quarter Ending JUNE 30, 2026 (Form 10-Q)

August 4, 2026

Vertex Reports Second Quarter 2026 Financial Results

August 3, 2026

Cystic Fibrosis Market, Global & Regional Now Available; Profiles Vertex Pharmaceuticals, AbbVie, and Other Frontrunner Competitors in Orphan Drug Markets

July 9, 2026

Vertex to Announce Second Quarter 2026 Financial Results on August 3rd

July 7, 2026

Vertex to Acquire Crinetics Pharmaceuticals

July 6, 2026

Vertex Announces US FDA Approval for Expanded Use of CASGEVY® for the Treatment of People Ages 2 Years and Older With Sickle Cell Disease or Transfusion-Dependent Beta Thalassemia

July 1, 2026

Vertex Announces US FDA Approval for Expanded Use of CASGEVY® for the Treatment of People Ages 2 Years and Older With Sickle Cell Disease or Transfusion-Dependent Beta Thalassemia

July 1, 2026

Vertex Presents New Data on CASGEVY®, Including First European Presentation of Data in Children Ages 5–11, at the European Hematology Association Congress and Announces Additional Global Regulatory Submissions

June 11, 2026

Vertex Presents New Data on CASGEVY®, Including First European Presentation of Data in Children Ages 5-11, at the European Hematology Association Congress and Announces Additional Global Regulatory Submissions

June 11, 2026

Vertex Presents New Data on ALYFTREK® at European Cystic Fibrosis Conference

June 5, 2026

Vertex Presents New Data on ALYFTREK® at European Cystic Fibrosis Conference

June 5, 2026

Vertex to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference on June 10

June 3, 2026

Vertex Announces US FDA Acceptance of Biologics License Application for Accelerated Approval of Povetacicept in IgA Nephropathy

June 1, 2026

Vertex Announces New Drug Submission for Suzetrigine Has Been Accepted for Review by Health Canada for the Treatment of Moderate-to-Severe Acute Pain in Adults

May 21, 2026

Vertex to Participate in Upcoming May Investor Conferences

May 11, 2026

Vertex Announces CASGEVY Reimbursement Agreement for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia in Germany

May 7, 2026

Vertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia in Germany

May 6, 2026

Vertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia in Germany

May 6, 2026

Quarterly Report for Quarter Ending MARCH 31, 2026 (Form 10-Q)

May 5, 2026

Vertex Reports First Quarter 2026 Financial Results

May 3, 2026

A Call to Action to Help Fight Kidney Failure in At-Risk Communities: American Kidney Fund Urges People to be APOL1 Aware

April 28, 2026

Halozyme Announces Global Collaboration and License Agreement with Vertex Pharmaceuticals for Hypercon™ Technology

April 7, 2026

Vertex to Announce First Quarter 2026 Financial Results on May 4th

April 6, 2026

Vertex Announces US FDA Approval for Label Extensions of ALYFTREK® and TRIKAFTA®, Expanding Availability of These Medicines to ~95% of All People With CF in the United States

April 1, 2026

Vertex Announces US FDA Approval for Label Extensions of ALYFTREK® and TRIKAFTA®, Expanding Availability of These Medicines to ~95% of All People With CF in the United States

March 31, 2026

Vertex Announces Positive Week 36 Interim Analysis Results for Primary and All Secondary Endpoints in the RAINIER Phase 3 Trial of Povetacicept in Adults With IgA Nephropathy

March 8, 2026

Vertex to Present New Data on JOURNAVX® That Demonstrates Effective Pain Management Following Aesthetic and Reconstructive Procedures

March 5, 2026

Vertex to Present New Data on JOURNAVX® That Demonstrates Effective Pain Management Following Aesthetic and Reconstructive Procedures

March 4, 2026

Vertex to Participate in TD Cowen 46th Annual Health Care Conference on March 3

February 17, 2026

Vertex Reports Fourth Quarter and Full Year 2025 Financial Results

February 12, 2026

Jupiter Endovascular Announces Completion of Enrollment in SPIRARE II Pivotal Trial

February 4, 2026

WuXi Biologics and Vertex Sign License and Research Service Agreement for T-cell Engager

February 1, 2026

Satellos Appoints Antoinette Paone as Chief Development Officer and Head of Regulatory Affairs

January 29, 2026

Vertex to Announce Fourth Quarter and Full Year 2025 Financial Results on February 12th

January 19, 2026

Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings

January 10, 2026

Vertex to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 12

December 21, 2025

Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions

December 6, 2025

Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions

December 5, 2025

Vertex to Participate in the Citi's 2025 Global Healthcare Conference on December 3

November 19, 2025

Vertex to Participate in the Citi’s 2025 Global Healthcare Conference on December 3

November 18, 2025

Vertex Presents Updated Phase 1/2 Data From RUBY-3 Study That Continue to Demonstrate Best-in-Class Potential for Povetacicept in Adults with IgA Nephropathy and Primary Membranous Nephropathy at American Society of Nephrology Kidney Week

November 7, 2025

Older news releases →

Calls

The 5 newest of 32 calls. Every call is listed under its year.

Decks

The 5 newest of 20 decks. Every deck is listed under its year.